A Pfizer lung cancer drug has been shown to greatly reduce tumor progression and improve survival outcomes for people in the advanced stages of a rare form of the disease, according to trial results published Friday. Lorlatinib, which is already approved and available under the brand name Lorbrena in the United States, was tested in […]
The post Pfizer drug extends life for people with rare form of lung cancer appeared first on Insider Paper.